Concert Pharmaceuticals, Inc.
CNCE
CNCE was delisted on the 3rd of March, 2023.
80 hedge funds and large institutions have $92.4M invested in Concert Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 15 closing their positions.
55% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 22
8% less funds holding
Funds holding: 87 → 80 (-7)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
54% less capital invested
Capital invested by funds: $202M → $92.4M (-$109M)
100% less call options, than puts
Call options by funds: $2K | Put options by funds: $1.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$7.37M |
| 2 |
ISL
Ingalls & Snyder LLC
New York
|
+$1.83M |
| 3 |
Morgan Stanley
New York
|
+$1.66M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.49M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$1.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$19.5M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$3.69M |
| 3 |
Millennium Management
New York
|
-$1.66M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.33M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.31M |
CNCE Hedge Fund Activity: Q3 2019 in Review
80 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Concert Pharmaceuticals, Inc. (CNCE) for Q3 2019, worth a combined $92.4M — down 54% from $202M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of CNCE and 8 opened new positions — a net loss of 7 holders — while 22 trimmed existing stakes and 34 added.
The largest buyer was Bank of America, adding an estimated $7.37M. The largest seller was BVF Inc, exiting entirely with an estimated $19.5M sold.
- 80 institutional investors held Concert Pharmaceuticals, Inc. (CNCE) as of Q3 2019, down from 87 in Q2 2019.
- Funds reported $92.4M of Concert Pharmaceuticals, Inc. stock for Q3 2019, down 54% quarter-over-quarter.
- 8 funds opened new Concert Pharmaceuticals, Inc. positions in Q3 2019 and 15 closed out, a net change of -7 holders.
- The largest Concert Pharmaceuticals, Inc. buyer in Q3 2019 was Bank of America, an estimated $7.37M added.
- The largest Concert Pharmaceuticals, Inc. seller in Q3 2019 was BVF Inc, an estimated $19.5M sold.
Based on aggregated 13F filings for Q3 2019.